Powered by
FARMINGTON HILLS—Ocuphire Pharma Inc., a startup pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, announced statistically significant and clinically …
CANTON TWP.—TrialAssure, developers of clinical trial management software, announced a limited release of a new product, Anonymize R, a document anonymization software that uses machine learning, natural language processing, and …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical startup developing a new class of cholesterol-fighting drugs, announced that its lead drug candidate, bempedoic acid, was included in the …
GRAND RAPIDS—The Grand Rapids-based pharmaceutical startup Tetra Therapeutics announced that new preclinical research suggests the ability of its investigational drug, BPN14770, to protect against memory loss and neuronal atrophy induced …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), the Ann Arbor pharma startup developing a new class of cholesterol-fighting drugs, announced positive top-line results from a Phase 2 clinical study of its combination …
GRAND RAPIDS—Tetra Discovery Partners, a clinical-stage biotechnology company, announced the company’s name change to Tetra Therapeutics. The name change reflects the company’s transition from a company focused on discovery research …
FARMINGTON HILLS—Ocuphire Pharma Inc., a clinical-stage pharmaceutical company developing therapies to treat patients with a variety of ophthalmic disorders, announced that it has closed on over $5 million of financing. …
CANTON TWP.–TrialAssure, a software company focused on developing clinical trial transparency tools, announced the launch of TrialResults.com, a new portal for sponsors to publicly share plain-language layperson summaries with clinical …
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical developer, announced positive results from the final Phase 3 test of its lead drug candidate, bempedoic acid. The …
ANN ARBOR — The pharma startup Millendo Therapeutics Inc. announced the start of a Phase 2b clinical trial to assess the efficacy of drug candidate MLE4901, a non-hormonal therapy for …